Biocidium Biopharmaceuticals

Biocidium Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on novel antibiotics, antifungals, and treatments for certain cancers. The company's primary focus is the development of antibiotics to treat serious multi-drug resistant (MDR) gram-positive and gram-negative bacterial infections. Additionally, Biocidium maintains strong antifungal and oncology programs and continues to build positive results in areas of skin treatments including psoriasis, acne, shingles, and eczema. With a significant IP portfolio, built over decades, and a focus on bio-pharma solutions, Biocidium’s proprietary high efficacy/low toxicity antibiotics represent innovative advances in a bio-based comprehensive solution to these harmful diseases. Notably, the company is one of the few that has developed both individual and combined gram-positive and gram-negative antibiotics. Biocidium fully understands the responsibility it has to develop, register, and treat life-threatening bacteria and conditions, aiming to help many patients by developing standalone solutions and compounds based on extensive expertise. The company’s antibiotics have shown 99.99999% efficacy against gram-negative and gram-positive drug-resistant organisms, including CRE (Carbapenem-resistant Enterobacteriaceae), VRE (Vancomycin-resistant Enterococcus), DRS (Drug-resistant Shigella), MRSA (Methicillin-resistant Staphylococcus aureus), VRSA (Vancomycin-resistant Staphylococcus aureus), MDPA (Multidrug-resistant Pseudomonas aeruginosa), and DRNG (Drug-resistant Neisseria gonorrhoeae). Founded in 2014, Biocidium operates within the biopharma, biotechnology, health care, and pharmaceutical industries, demonstrating a firm commitment to addressing critical medical challenges through innovative drug development.